** Drug developer Cellectar Biosciences' CLRB.O shares fall 44.3% to 71 cents premarket
** On Tuesday, CLRB said it may sell its experimental cancer drug to a larger firm or partner with it
** The decision follows discussions with the U.S. FDA on approval requirements for the drug - CLRB
** Co says it will lay off 60% of its employees to extend its operational runway into Q3 2025
** As of Dec. 31, 2023, CLRB had 20 employees - SEC filing
** As of last close, stock has fallen 53.8% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。